Reason to invest in NASDAQ:NTLA and NASDAQ:BEAM
Groundbreaking CRISPR Tech.
Promising Treatment Pipeline.
Big Pharma Partnerships.
Positioned to make a significant difference in healthcare.
This is only my second published idea and my last published trade was successful so with 100% accuracy the probability that this is going to pan out the way I want is infintesimal.
Here goes anyways. This is at what I would consider a key level of resistance permitting for a tight stop loss but decent gains possible. If it goes towards my price target will I...
Intellia Therapeutics Inc. NASDAQ: NTLA
Chart Overview 03/28/22
Intellia is trading in a 9-month downward channel pullback, closing the gap created by the release of Phase 1 data of NTLA-2001 to treat ATTR. The release caused a bull pennant that led to a reversal into a downward channel. We are tracking support at $56 and a resistance line is at $90. The...
Goals 61, 53. Invalidation at 110.
We are not in the business of getting every prediction right, no one ever does and that is not the aim of the game. The Fibonacci targets are highlighted in purple with invalidation in red. Fibonacci goals, it is prudent to suggest, are nothing more than mere fractally evident and therefore statistically likely levels that the...
We lost 89.95 so looks like we're gonna be bouncing around the channel again. Bottom of the channel is 51.11 so it may wanna wait before playing calls.
Intellia's Data Has Underlined Huge Potential Of Gene Therapeutics And There Will Be More Soon
Summary :
Intellia is a gene therapy specialist pioneering CRISPR-Cas9 technology.
Its recently released data in ATTR Amyloidosis stunned analysts, showing mean reduction in TTR Serum levels of up to 96%.
This was the first ever clinical proof of the safety and...
Not the best option possible, but the rebound that occurred is interesting. We "held" the trend during the week, as well as 50%, formally a large hidden . There may be an increase in the fact of holding the blue level.
11/ 05 /21 Oppenheimer Supports Performance 145,0
11/ 05 /21 HC Wainwright & Co. Supports Purchase 182.0
10/ 05 /21 Guggenheim Initiates Coverage...
Healthcare sector seems bullish overall. Lots of stocks within this sector have bullish bias as well.
NTLA have a pretty well defined ABCDE Triangle pattern, and any time now is a good time to enter.
Stop loss below the low of C i.e. around $140.
Disclaimer: I'm not giving any trading and investing advice. I'm just sharing my chart observations.
If you have...
Chart has consolidated very nicely since the earnings gap up. Since the gap up we have had sellers in control for a period of time (indicated by AVWAP from PEG) but has flipped to buyers being in control since price is above the AVWAP. As indicated with the white arrow it appears that this could be the higher low and we could be seeing some movement from this...
Keeping an eye on this name for tomorrow's session.
NTLA has been in a low volume consolidation since 'gaping' higher on the back of it's earnings. I'm not too concerned that I missed the reaction to earnings as my only goal is to be on the right side of the next 15 to 25%, whether that be long or short. In any case, I'm not always in favour of going into...
Price held at the 23EMA with a overall mixed week. Looking at the volume profile we are in between two strong nodes that have been controlling the trend. Price is below AVWAP but is moving sideways and not lower. Also have a declining 5EMA while lower term MA chop sideways as buyers and seller decide who is going to take control. Looking at the 30M timeframe...
